Hyperbaric Oxygen Therapy: A Surgeon’s Evidence-Based Take

There was a recent New York Times article discussing hyperbaric oxygen therapy as a potential longevity tool, and as a plastic surgeon who uses this therapy routinely, it struck me as an interesting lens on something that, in my world, is already very real, very clinical, and very effective. Hyperbaric oxygen is not new. It’s not fringe. It’s not speculative when used appropriately. In fact, in surgical practice, it has become one of the most reliable adjuncts we have for managing compromised tissue and improving healing in the right patients.

In my practice, we use hyperbaric oxygen both preoperatively and postoperatively, particularly in cases where blood flow is limited or at risk. That includes all mastectomy patients, many facelift patients, and even surgeries people don’t immediately associate with vascular compromise, such as abdominoplasty or fat grafting. Anytime you elevate tissue, reposition it, or rely on microcirculation to support survival, you are inherently dealing with a spectrum of ischemia. That’s where hyperbaric oxygen becomes clinically meaningful. When delivered correctly, typically at pressures of at least two atmospheres for ninety minutes or more, oxygen dissolves directly into plasma and tissue fluids, bypassing the need for red blood cell delivery. This is not theoretical physiology. You can see it in outcomes.

Looking at our own data across roughly five hundred patients, we saw complication rates drop by about half when postoperative hyperbaric therapy was incorporated appropriately. That’s not subtle. That’s not anecdotal. That’s the kind of signal that makes you change how you practice. For patients with marginal perfusion, it can mean the difference between tissue survival and tissue loss. For surgeons, it changes your threshold for risk, your recovery protocols, and your expectations.

The longevity conversation is where things become more interesting and, at the same time, more uncertain. There is emerging data suggesting that hyperbaric oxygen may reduce senescent cells, the so-called “zombie cells” that linger in tissue, contributing to inflammation and dysfunction, and may also influence telomere length, which is often used as a marker of cellular aging. From a plastic surgery perspective, that idea is particularly compelling. We spend so much time and energy trying to rejuvenate the skin through controlled injury, lasers, peels, and energy-based devices, all of which rely on inflammation and remodeling. The possibility of selectively targeting senescent cells, rather than broadly injuring tissue to stimulate repair, is an entirely different paradigm.

We’ve seen experimental models where senescent cells transferred into otherwise healthy tissue create a visibly aged, patchy, dull appearance. It’s not hard to extrapolate that concept to what we see clinically in aging skin. If hyperbaric oxygen can meaningfully reduce that burden, even partially, it opens the door to a different kind of anti-aging strategy, one that is less about damage and repair and more about cellular quality control. That said, this is where the conversation needs to remain grounded. The longevity claims are intriguing, but they are not yet at the same level of evidence as what we see in ischemic tissue and wound healing.

What concerns me more than the enthusiasm around longevity is the lack of attention to safety in many of the settings where hyperbaric oxygen is now being offered. This is not a benign wellness treatment. Oxygen under pressure is a powerful medical intervention with very real risks if handled improperly. Soft chambers, which are increasingly marketed in non-medical environments, do not achieve the pressures needed for true therapeutic effect and may create a false sense of benefit while introducing safety concerns. Oxygen is highly flammable, and hyperbaric environments require strict protocols, trained personnel, and properly engineered chambers.

Every legitimate hyperbaric chamber should be certified, inspected, and clearly labeled with identifying information, including its pressure capabilities and expiration or service parameters. Facilities should meet fire safety standards and operate under medical oversight. If those guardrails are not in place, patients should not be entering those chambers. The variability in quality between centers is significant, and it matters.

From where I sit, hyperbaric oxygen therapy is already a proven and valuable tool in surgery when used appropriately and in the right environment. The outcomes in ischemic and compromised tissue are not hypothetical. They are reproducible and clinically meaningful. The expansion into longevity and anti-aging is intriguing and worth studying, but it remains an extrapolation at this stage. I’m optimistic about where the science may lead, particularly in how we think about cellular aging and tissue quality, but I also think it’s important to separate what we know from what we hope.

For now, the takeaway is straightforward. In the right patients, in the right setting, hyperbaric oxygen therapy is not just helpful, it can be transformative. Outside of that, especially in poorly regulated environments, it can be ineffective at best and unsafe at worst. As with many things in medicine, the difference is not just the treatment itself, but how, where, and why it is used.